Lineage Cell Therapeutics, Inc. Income Statement

1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2009 Dec2010 Dec2011 Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 1.93M3.71M4.43M3.92M4.43M5.24M7.04M5.92M3.46M4.99M3.52M1.83M4.34M14.70M8.95M9.50M
Cost of Revenue 0.03M0.08M0.43M0.79M0.84M1.11M0.36M0.17M0.30M0.41M0.39M1.43M0.73M0.67M0.33M
Gross Profit 1.93M3.68M4.35M3.48M3.64M4.41M5.93M5.57M3.29M4.69M3.10M1.44M2.92M13.97M8.27M9.16M
Operating items
Research & Development -3.18M8.19M13.70M18.12M26.61M37.53M42.60M36.11M24.02M20.95M17.95M12.32M33.91M13.99M15.71M12.47M
Selling, General & Administrative -2.26M5.34M9.34M10.37M15.56M17.56M29.13M28.43M19.92M24.73M24.03M15.57M18.21M22.51M17.30M18.17M
Other Operating Expenses 10.89M-16.34M-38.78M-26.42M0.80M0.67M0.33M
Operating Expenses 5.45M13.53M23.04M28.48M59.63M55.09M71.74M64.53M43.95M46.48M41.98M27.89M52.13M36.49M33.68M30.98M
Operating Income -3.52M-9.85M-18.69M-25.00M-55.99M-50.68M-65.81M-58.97M-38.90M-41.80M-38.88M-26.45M-49.21M-22.52M-24.73M-21.48M
EBIT -3.52M-9.85M-18.69M-25.00M-55.99M-50.68M-65.81M-58.97M-38.90M-41.80M-38.88M-26.45M-49.21M-22.52M-24.73M-21.48M
Non-operating items
Non Operating Investment Income 1.16M-2.90M4.56M6.02M
Interest & Investment Income -0.09M-0.34M-0.75M-0.69M0.71M1.69M1.04M0.83M1.63M1.72M
Other Non Operating Income 0.03M-0.07M0.22M-0.32M-0.20M-0.38M3.69M-0.40M-2.80M-1.70M2.53M-3.78M-2.30M-2.15M-0.54M-0.67M
Non Operating Income -1.62M-2.34M0.24M-0.31M-0.20M-0.47M3.16M77.59M15.61M-5.33M19.64M4.52M5.94M-3.29M1.45M2.90M
Net income details
EBT -3.52M-9.85M-18.44M-25.31M-56.19M-51.16M-62.65M18.62M-23.29M-47.13M-19.23M-21.92M-43.27M-25.81M-23.28M-18.58M
Tax Provisions 0.35M-7.41M-1.24M0.54M-1.80M
Profit After Tax -5.14M-12.19M-18.44M-25.31M-52.91M-43.78M-58.13M33.57M-23.29M-46.78M-11.83M-20.68M-43.27M-26.35M-21.49M-18.61M
Equity Income -0.04M-4.67M3.21M8.00M3.10M-2.19M-0.18M-0.01M
Income from Non-Controlling Interests 0.00M-1.00M-1.93M-3.88M-9.03M-7.37M-11.14M-14.95M-3.31M-0.79M-0.12M-0.04M-0.25M-0.08M0.01M0.03M
Income from Continuing Operations -3.52M-9.85M-18.44M-25.31M-56.19M-51.16M-62.65M18.62M-23.29M-47.48M-11.83M-20.68M-43.27M-26.35M-21.48M-18.58M
Consolidated Net Income -3.52M-9.85M-18.44M-25.31M-56.19M-51.16M-62.65M18.62M-23.29M-47.48M-11.83M-20.68M-43.27M-26.35M-21.48M-18.58M
Income towards Parent Company -3.52M-9.85M-18.44M-25.31M-56.19M-51.16M-62.65M18.62M-23.29M-47.48M-11.83M-20.68M-43.27M-26.35M-21.48M-18.58M
Preferred Dividend Payments 0.09M-0.41M
Net Income towards Common Stockholders -3.52M-9.85M-18.44M-21.43M-43.88M-36.50M-47.41M33.57M-19.98M-47.48M-11.83M-20.68M-43.27M-26.35M-21.48M-18.58M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 33.31M47.36M50.25M54.91M67.20M83.12M94.89M103.39M126.87M126.96M149.79M149.99M168.56M169.98M174.99M188.84M
Shares Outstanding (Diluted Average) 66.47M79.71M99.55M114.48M169.79M172.66M200.19M
EBITDA -5.14M-10.29M-17.54M-21.36M-43.76M-50.68M-65.81M-58.97M-38.90M-41.80M-38.88M-26.45M-49.21M-22.52M-24.73M-21.48M
Tax Rate 38.51%5.65%7.74%